Vermillion study demonstrates Overa’s sensitivity in ovarian cancer detection

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Vermillion Inc. announced publication of a paper titled: “Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays for Presurgical Assessment for Ovarian Cancer Risk” in the journal Advanced Therapeutics (Shulman et al. Adv Ther. July 2019).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Health and Human Services Secretary Robert F. Kennedy Jr. is moving to overhaul the U.S. Preventive Services Task Force, a highly influential panel that determines which preventive services insurers must cover and guides routine medical care for millions of Americans. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login